Lineage Cell Therapeutics
LCTX
LCTX
115 hedge funds and large institutions have $152M invested in Lineage Cell Therapeutics in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 36 increasing their positions, 31 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
1.55% less ownership
Funds ownership: 52.41% → 50.87% (-1.5%)
2% less funds holding
Funds holding: 117 → 115 (-2)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
Holders
115
Holding in Top 10
2
Calls
$349K
Puts
$139K
Top Buyers
| 1 | +$1.76M | |
| 2 | +$1.09M | |
| 3 | +$655K | |
| 4 |
LCM
Laurion Capital Management
New York
|
+$472K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$234K |
Top Sellers
| 1 | -$3.35M | |
| 2 | -$1.13M | |
| 3 | -$907K | |
| 4 |
Two Sigma Investments
New York
|
-$472K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$359K |